Xenon Pharmaceuticals Inc (XENE) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $441.0M

XENE ranks #1999 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

317 institutions disclose a position in XENE, but none treat it as a major bet — even Affinity Asset Advisors, LLC, its most concentrated holder, allocates just 4.3% of its own portfolio to it.

BlackRock has added to its XENE position for two straight quarters, increasing it by $225.5M to reach $454.1M today.

Barclays PLC has trimmed its XENE position for two straight quarters, cutting it by $25.7M while still holding $1.2M.

XENE is up 0.3% today, and institutions have been net buyers of $441.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

XENE reported a net loss of $409.2M over the trailing twelve months.

• Not yet profitable — net loss of $409.2M over the trailing twelve months
• Revenue declined 82.8% year over year
• Net income declined year over year, from -$278.2M to -$409.2M
• Operating cash flow was negative, using $279.1M in cash
• Current ratio of 13.42x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range